Abstract: TH-PO0224
Treatment Satisfaction with Tenapanor (XPHOZAH): Real-World Survey of Patients with ESRD and Hyperphosphatemia
Session Information
- Bone and Mineral Metabolism: Clinical Reports and Practice
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 502 Bone and Mineral Metabolism: Clinical
Authors
- Kendrick, Jessica B., Division of Renal Disease and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Scott, Luisa, Ardelyx, Inc., Waltham, Massachusetts, United States
- Gist, Belinda, Ardelyx, Inc., Waltham, Massachusetts, United States
- Williams, Laura, Ardelyx, Inc., Waltham, Massachusetts, United States
Background
Tenapanor (TEN [XPHOZAH]), approved by the US FDA in October 2023, is indicated to reduce serum phosphorus (P) in adults with chronic kidney disease on dialysis as add-on therapy in patients (pts) who have an inadequate response to or are intolerant of any dose of phosphate binders (PBs). TEN inhibits P absorption via a different mechanism than PBs. Real-world (RW) data on pt experiences with TEN are limited. Here, we report results of a RW survey on pt perspectives of serum P management while on TEN for treatment of hyperphosphatemia (HP).
Methods
The survey was conducted via text messaging through the ArdelyxAssist pt assistance program and coupled to pharmacy data. Pts with HP on hemo- or peritoneal maintenance dialysis initiated TEN ≥7 weeks prior and were last dispensed TEN ≤12 weeks prior to the survey.
Results
There were 163 respondents. Of those with available data, 60% were male, median (SD) age was 60 (13) years, and median (SD) duration of TEN use was 133 (74) days. Many pts (39%) did not know their serum P control with TEN (Table). Excluding these pts, 74% (72/98) reported good/very good serum P control and 63% (37/59) reported improved control. For each additional month of TEN use, pts were less likely to respond "I don't know" (P<0.001) and more likely to report improved serum P control (P<0.05). Seventy-one percent of pts said TEN was easy to take. Median fill adherence was 94% and stable over time. Fifty-seven percent of pts reported an improved outlook on serum P management; 49% credited that improvement to better bowel movements (BMs), 33% to better serum P control, and 14% to lower pill burden.
Conclusion
Pts report positive experiences with TEN in the RW, including improved BMs, improved serum P control, and lower pill burden. The data highlight the ability of TEN to address important unmet needs in HP management in pts receiving maintenance dialysis.
Table. Patient survey results.
| How would you describe your current phosphorus (phosphate) control? Please only consider the time after starting TEN. (n=161) | Very poor | Poor | Fair | Good | Very good | I don’t know |
| 3.7% | 3.1% | 9.3% | 21.7% | 23.0% | 39.1% | |
| How have your phosphorus (phosphate) levels changed since starting TEN? (n=138) | Much higher or worse | A little higher or worse | No change | A little lower or better | Much lower or better | I don’t know |
| 1.5% | 1.5% | 13.0% | 9.4% | 17.4% | 57.3% | |
| How easy or difficult is it to remember to take TEN as prescribed? (n=97) | Very difficult | Difficult | Neither easy nor difficult | Easy | Very easy | – |
| 3.1% | 4.1% | 21.6% | 36.1% | 35.1% | – | |
| How has your outlook on phosphorus (phosphate) control changed since starting TEN? (n=101) | Much worse | A little worse | No change | A little better | Much better | – |
| 2.0% | 2.0% | 38.6% | 24.8% | 32.7% | – |
TEN, tenapanor.
Funding
- Commercial Support – Ardelyx, Inc.